Stocktoria
Bark, Inc. BARK
NYSE · XNYS · stock · Retail-Retail Stores, NEC · website · IPO 2020-11-11
Chart by TradingView
5/9
Piotroski F — financial health
-6.67
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $394.8M | $484.2M | $490.2M | $535.3M | $507.4M |
| Gross profit | $241.9M | $302.0M | $302.2M | $308.1M | $282.1M |
| Operating income | -$40.2M | -$35.1M | -$45.5M | -$63.8M | -$94.2M |
| Net income | -$39.0M | -$32.9M | -$37.0M | -$61.5M | -$68.3M |
| Operating cash flow | -$23.2M | -$7.1M | $6.1M | $4.7M | -$172.3M |
| Total assets | $170.0M | $260.6M | $298.6M | $400.4M | $434.1M |
| Total liabilities | $98.0M | $161.1M | $159.2M | $229.9M | $217.0M |
| Shareholders' equity | $72.0M | $99.5M | $139.4M | $170.5M | $217.1M |
| Ratios | |||||
| Gross margin | 61.3% | 62.4% | 61.6% | 57.6% | 55.6% |
| Operating margin | -10.2% | -7.3% | -9.3% | -11.9% | -18.6% |
| Net margin | -9.9% | -6.8% | -7.6% | -11.5% | -13.5% |
| Return on assets | -22.9% | -12.6% | -12.4% | -15.4% | -15.7% |
| Return on equity | -54.2% | -33.0% | -26.6% | -36.1% | -31.5% |
| Debt / equity | 0.00× | 0.43× | 0.29× | 0.48× | 0.35× |
| Current ratio | 1.86 | 1.63 | 2.94 | 3.14 | 3.39 |
| Revenue growth | -18.5% | -1.2% | -8.4% | 5.5% | 34.0% |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -6.67 (distress)
- Working capital / assets 0.331
- Retained earnings / assets -2.464
- EBIT / assets -0.236
- Equity / liabilities 0.735
Sector peers
WMT · CVS · COST · JD · HD · KR · all Retail Trade →
Source: SEC EDGAR filings · CIK 0001819574 · as of 2026-03-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.